Cefuroxime Axetil + Clavulanic Acid interactions

Checked as Cefuroxime + Clavulanic acid in this data source.

Full monograph for Cefuroxime Axetil + Clavulanic Acid Check it against another medicine

Medicines

479 documented

Severity

Mechanism

Medicines documented to interact with Cefuroxime Axetil + Clavulanic Acid, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Ketoconazolevia Clavulanic acid	Major	Synergy	Use of hepatotoxic drugs together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.	3 sources — open the full entry
Ketoconazole + Zinc Pyrithione + Aleoveravia Clavulanic acid	Major	Synergy	Use of hepatotoxic drugs together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.	3 sources — open the full entry
Leflunomidevia Cefuroxime, Clavulanic acid	Major	Synergy · Unknown	The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may…2 documented mechanisms	3 sources — open the full entry
Aluminium Hydroxide + Magnesium Hydroxidevia Cefuroxime	Moderate	Absorption	INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime…2 documented mechanisms	4 sources — open the full entry
Aluminium Hydroxide + Magnesium Hydroxide + Simethiconevia Cefuroxime	Moderate	Absorption	INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime…2 documented mechanisms	4 sources — open the full entry
Aluminium Oxide + Magnesium Trisilicatevia Cefuroxime	Moderate	Absorption	Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The…	4 sources — open the full entry
Amikacinvia Cefuroxime	Moderate	Synergy	Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported…	40 sources — open the full entry
Bacitracin Zinc + Polymyxin B Sulfatevia Cefuroxime	Moderate	Synergy	The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.2 documented mechanisms	2 sources — open the full entry
Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocainevia Cefuroxime	Moderate	Antagonism · Unknown	Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of…3 documented mechanisms	8 sources — open the full entry
Betamethasone + Clotrimazole + Gentamicinvia Cefuroxime	Moderate	Synergy · Unknown	Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported…2 documented mechanisms	40 sources — open the full entry
Betamethasone + Neomycin Sulphate (Ophthalmic)via Cefuroxime	Moderate	Synergy	Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported…	40 sources — open the full entry
Bumetanidevia Cefuroxime	Moderate	Synergy	Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of…	9 sources — open the full entry
Calcium acetate + Magnesium carbonatevia Cefuroxime	Moderate	Absorption	INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime…	4 sources — open the full entry
Calcium Carbonatevia Cefuroxime	Moderate	Absorption	INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime…	4 sources — open the full entry
Calcium Lactate Gluconate + Calcium Carbonate + Vitamin Cvia Cefuroxime	Moderate	Absorption	INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime…	4 sources — open the full entry
Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C + Vitamin D3via Cefuroxime	Moderate	Absorption	INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime…	4 sources — open the full entry
Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3via Cefuroxime	Moderate	Absorption	INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime…	4 sources — open the full entry
Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3 + Multimineralsvia Cefuroxime	Moderate	Absorption	INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime…	4 sources — open the full entry
Chloramphenicol (Oral)via Cefuroxime	Moderate	Antagonism	Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of…	8 sources — open the full entry
Chloramphenicol + Lidocaine Hydrochloridevia Cefuroxime	Moderate	Antagonism · Unknown	Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of…2 documented mechanisms	8 sources — open the full entry
Cinchocaine + Hydrocortisone + Framycetin + Esculinvia Cefuroxime	Moderate	Synergy · Unknown	Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported…2 documented mechanisms	40 sources — open the full entry
Cinchocaine + Hydrocortisone + Neomycin + Esculinvia Cefuroxime	Moderate	Synergy · Unknown	Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported…2 documented mechanisms	40 sources — open the full entry
Clobetasol Propionate + Neomycin Sulphate + Nystatinvia Cefuroxime	Moderate	Synergy · Unknown	Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported…3 documented mechanisms	40 sources — open the full entry
Colistimethate Sodiumvia Cefuroxime	Moderate	Synergy	The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.	2 sources — open the full entry
Cyproterone Acetate + Ethinyl Estradiolvia Cefuroxime	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Dexamethasone + Chloramphenicolvia Cefuroxime	Moderate	Antagonism · Unknown	Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of…2 documented mechanisms	8 sources — open the full entry
Dexamethasone + Neomycin + Glacial Acetic Acidvia Cefuroxime	Moderate	Synergy · Unknown	Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported…2 documented mechanisms	40 sources — open the full entry
Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphatevia Cefuroxime	Moderate	Synergy · Unknown	Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported…3 documented mechanisms	42 sources — open the full entry
Dexamethasone + Tobramycinvia Cefuroxime	Moderate	Synergy · Unknown	Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported…2 documented mechanisms	40 sources — open the full entry
Dexlansoprazolevia Cefuroxime	Moderate	Absorption	The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of…	4 sources — open the full entry
Dienogest + Estradiol Valeratevia Cefuroxime	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Drospirenone + Estradiolvia Cefuroxime	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Drospirenone + Ethinyl Estradiol0.02 mg 0.03 mgvia Cefuroxime	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Drospirenone + Ethinyl Estradiol + Levomefolatevia Cefuroxime	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Efavirenzvia Clavulanic acid	Moderate	Synergy	Coadministration of efavirenz with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Efavirenz has been associated with…	7 sources — open the full entry
Entecavir Monohydratevia Cefuroxime	Moderate	Excretion	Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or…	2 sources — open the full entry
Epirubicin Hydrochloridevia Clavulanic acid	Moderate	Synergy	The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes…	4 sources — open the full entry
Esomeprazolebase MUPS preparationvia Cefuroxime	Moderate	Absorption	The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of…	4 sources — open the full entry
Esomeprazole + Amoxicillin + Clarithromycinvia Cefuroxime	Moderate	Absorption · Unknown	The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of…3 documented mechanisms	4 sources — open the full entry
Estradiolbase vaginal creamvia Cefuroxime	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Estradiol + Dydrogesteronevia Cefuroxime	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Estradiol Hemihydrate + Progesterone Micronizedvia Cefuroxime	Moderate	Antagonism · Unknown	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…2 documented mechanisms	38 sources — open the full entry
Estradiol Valeratevia Cefuroxime	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Ethinyl Estradiol + Desogestrel0.02 mg 0.03 mgvia Cefuroxime	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Ethinyl Estradiol + Gestodenevia Cefuroxime	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Ethinyl Estradiol + Levonorgestrel + Ferrous Fumaratevia Cefuroxime	Moderate	Antagonism · Unknown	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…2 documented mechanisms	38 sources — open the full entry
Ethinyl Estradiol + Lynestrenol0.0375 mg 0.05 mgvia Cefuroxime	Moderate	Antagonism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	38 sources — open the full entry
Famotidinevia Cefuroxime	Moderate	Absorption	The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of…	4 sources — open the full entry
Fluocinolone Acetonide + Neomycin Sulfatevia Cefuroxime	Moderate	Synergy	Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported…	40 sources — open the full entry
Fluormetholone + Neomycin Sulphatevia Cefuroxime	Moderate	Synergy	Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported…	40 sources — open the full entry

Conditions

Conditions in which Cefuroxime Axetil + Clavulanic Acid needs care, as documented in this source.

Colitis
Major
Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.
31 sources
1. "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories (2002):
2. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome (2002):
3. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
4. "Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn (2002):
5. "Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
6. "Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
7. "Product Information. Amoxil (amoxicillin)." SmithKline Beecham (2001):
8. "Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals (2001):
Show all 31 sourcesShow fewer sources
1. "Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis (2001):
2. "Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn (2001):
3. "Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc (2003):
4. "Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals (2004):
5. "Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical (2007):
6. "Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc (2009):
7. "Product Information. Vibativ (telavancin)." Theravance Inc (2009):
8. "Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals (2010):
9. "Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc (2022):
10. "Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc. (2014):
11. "Product Information. Orbactiv (oritavancin)." The Medicines Company (2014):
12. "Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions (2017):
13. "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc. (2017):
14. "Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC (2022):
15. "Product Information. Zemdri (plazomicin)." Achaogen (2018):
16. "Product Information. Seysara (sarecycline)." Allergan Inc (2018):
17. "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc. (2018):
18. "Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc. (2018):
19. "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc (2019):
20. "Product Information. Biaxin (clarithromycin)." AbbVie US LLC (2019):
21. "Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group (2021):
22. "Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals (2018):
23. "Product Information. Priftin (rifapentine)." sanofi-aventis (2020):
Diabetes Mellitus
Moderate
A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy. Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.
2 sources
1. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome (2002):
2. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
Diseases requiring dialysis
Moderate
Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis. A supplemental dose should be given at the end of each hemodialysis session. There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.
2 sources
1. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome (2002):
2. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
Epilepsy
Moderate
Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced. If seizures associated with drug therapy occur, cefuroxime should be discontinued. Anticonvulsant therapy can be administered if clinically indicated.
1 source
1. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
Heart Failure
Moderate
Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity. The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.
1 source
1. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
Kidney Diseases
Moderate
Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites. The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function. Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents. Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling. Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.
21 sources
1. "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories (2002):
2. "Product Information. Ancef (cefazolin)." SmithKline Beecham (2002):
3. "Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn (2002):
4. "Product Information. Monocid (cefonicid)." SmithKline Beecham (2002):
5. "Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel (2002):
6. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals (2002):
7. "Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc (2002):
8. "Product Information. Fortaz (ceftazidime)." Glaxo Wellcome (2002):
Show all 21 sourcesShow fewer sources
1. "Product Information. Tazicef (ceftazidime)." SmithKline Beecham (2002):
2. "Product Information. Cefizox (ceftizoxime)." Fujisawa (2002):
3. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome (2002):
4. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
5. "Product Information. Keflin (cephalothin)." Lilly, Eli and Company (2002):
6. "Product Information. Cefadyl (cephapirin)." Apothecon Inc (2002):
7. "Product Information. Staphcillin (methicillin)." Apothecon Inc (2002):
8. "Product Information. Pfizerpen (penicillin)." Roerig Division (2001):
9. "Product Information. Pipracil (piperacillin)." Lederle Laboratories (2001):
10. "Product Information. Ticar (ticarcillin)." SmithKline Beecham (2001):
11. "Product Information. Mandol (cefamandole)." Lilly, Eli and Company (2001):
12. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb (2001):
13. "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc (2019):
Liver Diseases
Moderate
Cases of hepatitis have been reported with the use of certain cephalosporins. Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed. Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.
20 sources
1. "Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn
2. "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company (2002):
3. "Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb (2002):
4. "Product Information. Ancef (cefazolin)." SmithKline Beecham (2002):
5. "Product Information. Kefzol (cefazolin)." Lilly, Eli and Company (2002):
6. "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc (2002):
7. "Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel (2002):
8. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals (2002):
Show all 20 sourcesShow fewer sources
1. "Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc (2002):
2. "Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb (2002):
3. "Product Information. Fortaz (ceftazidime)." Glaxo Wellcome (2002):
4. "Product Information. Cefizox (ceftizoxime)." Fujisawa (2002):
5. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome (2002):
6. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
7. "Product Information. Keflex (cephalexin)." Dista Products Company (2002):
8. "Product Information. Cedax (ceftibuten)." Schering-Plough (2001):
9. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb (2001):
10. "Product Information. Omnicef (cefdinir)." Parke-Davis (2001):
11. "Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals (2001):
12. "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc (2001):
Vitamin K Deficiency
Moderate
Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time. Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy. Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).
3 sources
1. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals (2002):
2. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
3. "Product Information. Keflex (cephalexin)." Dista Products Company (2002):

Therapeutic duplication

Drug classes that overlap with Cefuroxime Axetil + Clavulanic Acid, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.

beta-lactam antibiotics
The recommended maximum number of medicines in the 'beta-lactam antibiotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'beta-lactam antibiotics' category.
Example product in the source data (US market): Prevpac
beta-lactam antibiotics
The recommended maximum number of medicines in the 'beta-lactam antibiotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'beta-lactam antibiotics' category.
Example product in the source data (US market): Amoxicillin/clarithromycin/omeprazole
beta-lactam antibiotics
The recommended maximum number of medicines in the 'beta-lactam antibiotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'beta-lactam antibiotics' category.
Example product in the source data (US market): Amoxicillin/omeprazole/rifabutin

Medicines

Conditions

Colitis

Diabetes Mellitus

Diseases requiring dialysis

Epilepsy

Heart Failure

Kidney Diseases

Liver Diseases

Vitamin K Deficiency

Therapeutic duplication

beta-lactam antibiotics

beta-lactam antibiotics

beta-lactam antibiotics